At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 33 enrolled
Drug / intervention
dronedarone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
SOAR: Study Observing Antiarrhythmic Remodelling Using LGE-MRI
In Brief
A Phase 3 clinical trial evaluating dronedarone and Placebo for Atrial Fibrillation. Completed, enrolled 33 participants.
Detailed Summary
The primary objective of this study is to demonstrate how dronedarone (Multaq®) may aid in the slowing of progression of left atrial and ventricular fibrosis in patients with atrial fibrillation as assessed by late gadolinium enhanced magnetic resonance imaging.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
Countries--
CollaboratorsSanofi
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2010
Enrollment StartNov 2010
Primary CompletionDec 2012
TodayJul 2026
First PostedAug 16, 2010
Enrollment StartNov 1, 2010
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 15.9 years ago
Interventions
dronedaronedrug
Dronedarone will be prescribed by the patient's team according to established guidelines.
Placebodrug
Placebo will be administered by the patient's team according to established guidelines.